ANCA vasculitis nephropathy is usually not completely cured; clinical remission can be achieved with active treatment, but recurrence is still possible. ANCA-associated vasculitis is an autoimmune disease pathologically characterized by inflammation and fibrinoid necrosis of small blood vessel walls. The main manifestations are renal involvement, such as hematuria, proteinuria, and decreased renal function, in addition to pulmonary, cutaneous, and joint manifestations, such as cough, hemoptysis, rash, and joint pain. The disease can be induced by high-dose hormone (injectable methylprednisolone sodium succinate) or hormone combined with immunosuppressant (cyclophosphamide), etc., which can enable patients to achieve clinical remission, after which they need to be maintained in order to achieve long-term remission of the disease, at which time they need to take a small dose of glucocorticosteroids (prednisone acetate) combined with immunosuppressant (cyclophosphamide and azathioprine) for a long period of time. Even with active and effective treatment, there is still a possibility of relapse. Therefore, patients must take the medication as prescribed by the doctor, and must not stop the medication on their own to avoid disease progression or relapse. Patients with ANCA vasculitis nephropathy are recommended to consult regular hospitals and receive standardized treatment under the guidance of physicians.